Inaktiver Wert

Andere Sprachen Immunovant, Inc. Nasdaq

Aktien

A2PXDP

US45258J2015

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	30.05.
Immunovant Q4 Loss Widens -- Shares Fall After-Hours	29.05.
Immunovant, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	29.05.
Immunovant, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	29.05.
Immunovant Insider Sold Shares Worth $479,233, According to a Recent SEC Filing	24.05.
Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	20.04.
Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	20.04.
IMMUNOVANT, INC. : Oppenheimer désormais positif sur le dossier	28.03.
IMMUNOVANT, INC. : Goldman Sachs maintient sa recommandation à l'achat	13.03.
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing	23.02.
IMMUNOVANT, INC. : JPMorgan Chase relève sa recommandation à acheter	20.02.
IMMUNOVANT, INC. : Wolfe Research passe à l'achat	15.02.
Immunovant Posts Narrower Fiscal Q3 Loss	12.02.
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12.02.
Immunovant Insider Sold Shares Worth $383,012, According to a Recent SEC Filing	29.01.
Transcript : Immunovant, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM	09.01.
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	21.12.
IMMUNOVANT, INC. : HC Wainwright maintient sa recommandation à l'achat	21.12.
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours	20.12.
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates	20.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immunovant, Inc. Nasdaq

Aktien

A2PXDP

US45258J2015

Andere Sprachen

Filter